Status:
RECRUITING
Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insu...
Detailed Description
The study will consist of creation a tumor tissue bank, all sampling will be stored in the biological resources center of Ambroise Paré hospital.
Eligibility Criteria
Inclusion
- Diagnosed NSCLC or SCLC;
- Patient treated priorly by ICI and progressed under ICI;
- Have provided written informed consent for the study;
- Be \>/= 18 years of age on day of signing informed consent.
Exclusion
- Patient under guardianship or curatorship;
- Unable to provide written informed consent for the study;
- Technical impossibility to carry out tissular rebiopsy under local anesthesia.
Key Trial Info
Start Date :
August 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04300062
Start Date
August 18 2020
End Date
August 1 2027
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
Boulogne-Billancourt, France, 92100